Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study
Primary Objective
To demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS).
This Study is
No Longer Enrolling
Details
Age
Adult
Phase
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 16-1727
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers